Advances in antiretroviral therapyArribas, Jose R.a,b; Eron, Josepha,bCurrent Opinion in HIV and AIDS: July 2013 - Volume 8 - Issue 4 - p 341–349 doi: 10.1097/COH.0b013e328361fabd THIRTY YEARS OF HIV AND AIDS: Edited by David A. Cooper and Giuseppe Pantaleo Abstract Author Information Purpose of review To review recent data about advances in ART. Recent findings In the last 2 years, clinical trials have demonstrated the safety and efficacy of three integrase transfer inhibitors [raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG)], one new nonnucleoside reverse transcriptase inhibitor [rilpivirine (RIL)] and a new extended release formulation of nevirapine in antiretroviral-naive and experienced patients. Cobicistat (COBI), a new pharmacologic enhancer without antiretroviral activity has been studied as a booster of EVG and atazanavir (ATV). Two new single-pill fixed-dose combinations (FDCs) have been approved by regulatory agencies: RIL/tenofovir (TDF) difumarate/emtricitabine and elvitegravir/COBI/TDF difumarate/emtricitabine. A new prodrug of TDF is going to be evaluated in phase III clinical trials with the goal of showing less bone and renal toxicity. Ongoing trials are evaluating the use of nucleoside sparing regimens in antiretroviral-naive patients. Generic formulations of multiple antiretrovirals would become available in the immediate future. The efficacy and price reduction associated with generic antiretrovirals remains to be elucidated. Summary In the last 2 years, the antiretroviral armamentarium has been significantly expanded by the advent of the integrase transfer inhibitors RAL, EVG and DTG, by a new nonnucleoside reverse transcriptase inhibitor, RIL and by two new single-pill FDCs. aServicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ. Madrid, Spain bDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Correspondence to Dr Jose R. Arribas, Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ. Madrid, Spain. Tel: +34 91 297 1676; fax: +34 91 358 1407; e-mail: firstname.lastname@example.org © 2013 Lippincott Williams & Wilkins, Inc.